Current Clinical Oncology

Melanoma

Biologically Targeted Therapeutics

Editors: Borden, Ernest C. (Ed.)

Buy this book

eBook $74.99
price for USA (gross)
  • ISBN 978-1-59259-159-6
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $99.00
price for USA
  • ISBN 978-0-89603-876-9
  • Free shipping for individuals worldwide
  • This title is currently reprinting. You can pre-order your copy now.
Softcover $99.00
price for USA
  • ISBN 978-1-4684-9668-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

Substantial progress in the effective prevention and treatment of primary and recurrent melanomas is now being regularly achieved using therapeutic proteins and cells. In Melanoma: Biologically Targeted Therapeutics, Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. Throughout, the focus is on providing the rationale and background by which the many promising biologically targeted therapies are translated via clinical trials into effective new therapies. Among the interventional agents treated are cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These therapies include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (NF-kB and IL-8) for antiangiogenesis therapies.
State-of-the-art and forward looking, Melanoma: Biologically Targeted Therapeutics critically evaluates the biological, cellular, and targeted therapies that are already reducing mortality from primary melanomas, and are expected increasingly to continue so for the foreseeable future.

Reviews

"Incredible detail to immunologic mechanisms is the strong point of the book. The bibliography at the end of each chapter is exhaustive, sometimes citing over 300 references.The pharmacokinetics of cytokines are meticulously discussed and diagrammed. Tables summarizing the results of clinical trials to date are peppered throughout the book. The authors are careful not to draw conclusions that do not have support from prospective randomized clinical trials. It is an excellent source to become familiar with current research and experimental protocols for advanced melanoma. Researchers and directors of melanoma clinics at tertiary care facilities will want to have this book as a resource."-Weighted Numerical Score: 100 - 5 Stars!-Doody's Health S ciences Book Review Journal

Table of contents (13 chapters)

  • Management of Primary Malignant Melanoma

    Bailin, Philip L. (et al.)

    Pages 3-38

  • A Pathologist’s Perspective on Prognostic Features of Malignant Melanoma

    Tuthill, Ralph J.

    Pages 39-72

  • Clinical Prognostic Factors and Staging

    Daw, Hamed (et al.)

    Pages 73-92

  • Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression

    Cohen, Peter A. (et al.)

    Pages 95-139

  • Immunotherapy of Advanced Melanoma Directed at Specific Antigens

    Leong, Stanley P. L. (et al.)

    Pages 141-156

Buy this book

eBook $74.99
price for USA (gross)
  • ISBN 978-1-59259-159-6
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $99.00
price for USA
  • ISBN 978-0-89603-876-9
  • Free shipping for individuals worldwide
  • This title is currently reprinting. You can pre-order your copy now.
Softcover $99.00
price for USA
  • ISBN 978-1-4684-9668-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Melanoma
Book Subtitle
Biologically Targeted Therapeutics
Editors
  • Ernest C. Borden
Series Title
Current Clinical Oncology
Copyright
2002
Publisher
Humana Press
Copyright Holder
Springer Science+Business Media New York
eBook ISBN
978-1-59259-159-6
DOI
10.1007/978-1-59259-159-6
Hardcover ISBN
978-0-89603-876-9
Softcover ISBN
978-1-4684-9668-0
Series ISSN
2364-1134
Edition Number
1
Number of Pages
XVI, 388
Topics